Thalassemia: Understanding This Inherited Blood Disorder

Thalassemia is a group of autosomal recessive hemoglobinopathies caused by reduced or absent synthesis of globin chains (α or β), leading to ineffective erythropoiesis and hemolysis.

Classification

  • Alpha-thalassemia: α-globin gene (HBA1/HBA2) deletions (1–4 alleles). Silent carrier (1), trait (2), HbH disease (3), Hb Bart’s hydrops fetalis (4 – lethal).
  • Beta-thalassemia: β-globin gene (HBB) mutations (β⁰ = no production, β⁺ = reduced).
    • Minor (trait): heterozygous, asymptomatic/mild anemia.
    • Intermedia: variable severity, transfusion-independent.
    • Major (Cooley’s anemia): homozygous/compound heterozygous β⁰/β⁺ – severe transfusion-dependent anemia from infancy.

Pathophysiology

  • Globin chain imbalance → excess unpaired chains precipitate → membrane damage → ineffective erythropoiesis (marrow apoptosis) + hemolysis.
  • Expansive marrow → bone deformities (frontal bossing, chipmunk facies), extramedullary hematopoiesis (splenomegaly).
  • Iron overload from transfusions + increased absorption → cardiomyopathy, cirrhosis, endocrine failure.

Diagnosis

  • CBC: microcytic hypochromic anemia (low MCV/MCH disproportionate to anemia), high RBC count (thalassemia trait), target cells, basophilic stippling.
  • Hemoglobin electrophoresis/HPLC: ↑HbA2 (>3.5%) = β-trait; ↑HbF = β-major/intermedia or δβ-thalassemia; HbH (β4) = α-thalassemia.
  • Genetic testing: definitive for α-thalassemia, prenatal/PGT.

Management

  • Transfusion-dependent: Regular PRBCs (pre-leukoreduced, extended phenotype) to maintain Hb 9–10 g/dL; iron chelation (deferasirox, deferiprone, deferoxamine) from ~10–20 transfusions / ferritin >1000.
  • Non-transfusion-dependent: Folic acid, monitor growth, splenectomy if hypersplenism (post-vaccination), luspatercept (approved for β-thalassemia anemia).
  • Curative: Allogeneic HCT (matched sibling best); gene therapy (betibeglogene autotemcel / Zynteglo) approved for β-thalassemia major.

Comprehensive care at thalassemia centers improves survival into 5th–6th decade.

Blood Disorders - Related Articles